{"downloaded": true, "htmlmade": false, "full": {"id": "33847614", "source": "MED", "pmid": "33847614", "pmcid": "PMC8052020", "fullTextIdList": {"fullTextId": "PMC8052020"}, "doi": "10.1097/md.0000000000025097", "title": "Use of Shenhuang paste on Shenque point improves chemotherapy induced gastrointestinal toxicity in breast cancer: A protocol for randomized controlled trial.", "authorString": "Wang R, Shi Y, Xie X, Ge Q, Xu J, Sun Q, Xu X.", "authorList": {"author": [{"fullName": "Wang R", "firstName": "Rongyun", "lastName": "Wang", "initials": "R", "authorId": {"@type": "ORCID", "#text": "0000-0002-7201-3201"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "School of Nursing, Zhejiang Chinese Medical University."}}}, {"fullName": "Shi Y", "firstName": "Yanan", "lastName": "Shi", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "School of Nursing, Zhejiang Chinese Medical University."}}}, {"fullName": "Xie X", "firstName": "Xiaohong", "lastName": "Xie", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Zhejiang Provincial Hospital of Chinese Medicine."}}}, {"fullName": "Ge Q", "firstName": "Qinling", "lastName": "Ge", "initials": "Q", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Zhejiang Provincial Hospital of Chinese Medicine."}}}, {"fullName": "Xu J", "firstName": "Jingming", "lastName": "Xu", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China."}}}, {"fullName": "Sun Q", "firstName": "Qiuhua", "lastName": "Sun", "initials": "Q", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "School of Nursing, Zhejiang Chinese Medical University."}}}, {"fullName": "Xu X", "firstName": "Xiaohong", "lastName": "Xu", "initials": "X", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Zhejiang Provincial Hospital of Chinese Medicine."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-7201-3201"}}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "15", "volume": "100", "journalIssueId": "3151395", "dateOfPublication": "2021 Apr", "monthOfPublication": "4", "yearOfPublication": "2021", "printPublicationDate": "2021-04-01", "journal": {"title": "Medicine", "ISOAbbreviation": "Medicine (Baltimore)", "medlineAbbreviation": "Medicine (Baltimore)", "NLMid": "2985248R", "ISSN": "0304-5412", "ESSN": "1536-5964"}}, "pubYear": "2021", "pageInfo": "e25097", "abstractText": "<h4>Background</h4>Breast cancer, a malignant disorder, occurs in the epithelial tissue of the breast gland. Chemotherapy is the standard treatment for breast cancer, however, the side effect, especially gastrointestinal dysfunction, due to chemotherapy still remain major problems. Traditional Chinese Medicine has been proven therapeutically effective on reducing adverse effects caused by chemotherapy. Shenhuang Plaster.<h4>Methods</h4>The study is a randomized, placebo-controlled, blind trial. A total of 160 Chinese breast cancer patients will be enrolled and randomly allocated into the experimental group and control group in a 1:1 ratio. Patients in the experimental group will be prescribed Shenhuang plaster application on shenque point (CV8) plus chemotherapy treatment. Patients in the control group will be prescribed placebo plaster application on CV8 plus chemotherapy treatment. The acupoint application will last 3\u200adays. The primary outcome will be the form of faces every day, and the secondary outcomes the symptom score of traditional Chinese medicine, the changes of fecal bacteria and metabolites, serum motilin, gastrin and ghrelin levels.<h4>Discussion</h4>This study is to observe therapeutic effects with Shenhuang plaster application on CV8 to regulate chemotherapy-induced gastrointestinal toxicity in breast cancer patients.<h4>Trial registration</h4>Chinese Clinical Trial Registry (http://www.chictr.org.cn/showproj.aspx?proj=55262) No. ChiCTR2000034313. Registered on July 2, 2020.", "affiliation": "School of Nursing, Zhejiang Chinese Medical University.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial Protocol", "research-article", "Randomized Controlled Trial", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "LGF19H270002", "agency": "Zhejiang Province Public Welfare Technology Application Research Project", "orderIn": "0"}, {"grantId": "National Natural Science", "agency": "Innovative Research Group Project of the National Natural Science Foundation of China", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Breast Neoplasms", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Gastrointestinal Diseases", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "Y"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Drugs, Chinese Herbal", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Agents", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "Y"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Administration, Topical"}, {"majorTopic_YN": "N", "descriptorName": "Double-Blind Method"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "China"}, {"majorTopic_YN": "N", "descriptorName": "Female"}]}, "chemicalList": {"chemical": [{"name": "Antineoplastic Agents", "registryNumber": "0"}, {"name": "Drugs, Chinese Herbal", "registryNumber": "0"}]}, "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1097/MD.0000000000025097"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC8052020"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC8052020?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "0", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2021-04-28", "dateOfCreation": "2021-04-13", "firstIndexDate": "2021-04-14", "fullTextReceivedDate": "2021-04-28", "dateOfRevision": "2021-04-28", "firstPublicationDate": "2021-04-01"}, "htmllinks": "https://europepmc.org/articles/PMC8052020", "abstract": "<h4>Background</h4>Breast cancer, a malignant disorder, occurs in the epithelial tissue of the breast gland. Chemotherapy is the standard treatment for breast cancer, however, the side effect, especially gastrointestinal dysfunction, due to chemotherapy still remain major problems. Traditional Chinese Medicine has been proven therapeutically effective on reducing adverse effects caused by chemotherapy. Shenhuang Plaster.<h4>Methods</h4>The study is a randomized, placebo-controlled, blind trial. A total of 160 Chinese breast cancer patients will be enrolled and randomly allocated into the experimental group and control group in a 1:1 ratio. Patients in the experimental group will be prescribed Shenhuang plaster application on shenque point (CV8) plus chemotherapy treatment. Patients in the control group will be prescribed placebo plaster application on CV8 plus chemotherapy treatment. The acupoint application will last 3\u200adays. The primary outcome will be the form of faces every day, and the secondary outcomes the symptom score of traditional Chinese medicine, the changes of fecal bacteria and metabolites, serum motilin, gastrin and ghrelin levels.<h4>Discussion</h4>This study is to observe therapeutic effects with Shenhuang plaster application on CV8 to regulate chemotherapy-induced gastrointestinal toxicity in breast cancer patients.<h4>Trial registration</h4>Chinese Clinical Trial Registry (http://www.chictr.org.cn/showproj.aspx?proj=55262) No. ChiCTR2000034313. Registered on July 2, 2020.", "pdflinks": "https://europepmc.org/articles/PMC8052020?pdf=render", "journaltitle": "Medicine", "authorinfo": ["Wang R", "Shi Y", "Xie X", "Ge Q", "Xu J", "Sun Q", "Xu X"], "title": "Use of Shenhuang paste on Shenque point improves chemotherapy induced gastrointestinal toxicity in breast cancer: A protocol for randomized controlled trial."}